P/E của cổ phiếu FBIO là bao nhiêu?

Fortress Biotech Inc (FBIO) hiện giao dịch ở mức P/E 0.69 lần.

ROE của cổ phiếu FBIO là bao nhiêu?

Fortress Biotech Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 78.77%.

Tỷ suất cổ tức của FBIO là bao nhiêu?

Fortress Biotech Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của FBIO là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của FBIO ở mức 77/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu FBIO không?

Điểm AI Timing của FBIO là 56/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu FBIO thuộc ngành nào?

Fortress Biotech Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu FBIO (NASDAQ) | Fortress Biotech Inc

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

FBIO AI Analysis Summary

Our AI summary for FBIO: Fortress Biotech Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.69, ROE of 78.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

FBIO

Fortress Biotech Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 2.79

0.07 (2.57%) Day Change

Watchlist Portfolio Compare Chart

0.69

P/E

0.26

D/E

78.8%

ROE

35.8%

ROA

0.00%

Div Yield

-0.01

PEG

FORTRESS BIOTECH INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.79 Price 0.07 (2.57%) Day Change	NEWS SCORE: 98

FBIO Chất lượng tổng thể của cố phiếu Tốt ( Chất lượng = 77) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

64%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	532
Magic Formula Rank by ROE	532
Magic Formula Rank by ROIC	409
Price	2.79
PBV / Sector	0.45 / 44,105.10 GREAT
Earning Per Share	3.95

PE / Sector	0.69 / 19.37 GREAT
PEG or PE/Growth / Sector	-0.01 / 1.06
Average 1M Daily Value	2.32 M GREAT
Average 1W Daily Value	2.90 M GREAT

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	193.12 / 97.23 GREAT
NPM Average (%) / Sector	-12.38 / -1,697.84
NPM Change Average (%) / Sector	388.28 / 5,097.59 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	35.80 / 185,260.64 GREAT
ROA Average (%) / Sector	-11.61 / 36,684.64
ROA Change Average (%) / Sector	193.61 / 422,221.42 GREAT
ROE (%) / Sector	78.77 / 243,761.81 GREAT
ROE Average (%) / Sector	-117.27 / 48,758.38
ROE Change Average (%) / Sector	93.63 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Chi tiết đăng ký

Analyze Date	2026-08-06 07:59:58
Symbol	FBIO
Name	FORTRESS BIOTECH INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	33.22 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	90.36 / 9,702.21

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Phone: 781 652 4500

Website: https://www.fortressbiotech.com

Employees: 78

Sector: Healthcare >> Biotechnology

Description: Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.